cause (rates after 10 years 21% vs. 71%, p ! 0.0001), diseasespecific (12 vs. 37%, p = 0.009) and competing mortality (9 vs. 33%, p = 0.02) differed significantly. Conclusions: Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer may be attributed to increased competing mortality, possibly caused by an interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer.
Introduction
In the Western world, prostate cancer is the most common solid organ malignancy in males [1] . In contrast to many other cancers, lymph node involvement in prostate cancer is frequently associated with long-term survival although definite cure is improbable. The prognostic factors predicting survival in men with lymph node-positive prostate cancer are still poorly defined [2] . In this study, we evaluated several tumor-related and host-related variables as potential predictors of survival in this population. Prognosis 
Patients and Methods

Patient Sample
Between December 1st, 1992 and December 31st, 2005, of 2,205 patients consecutively treated by radical prostatectomy, 194 had histopathologically proven lymph node involvement and constituted the study group. Those in whom surgery was aborted after lymph node dissection were excluded. Institutional review board approval was obtained. Lymph node dissection was done along the external iliac vessels, with the bifurcation of the common iliac artery as proximal border and in the obturator fossa. The number of tumor-positive lymph nodes was available in all cases. The number of removed lymph nodes was available in 189/194 patients. The mean number of removed nodes was 14 (range 4-42) in those patients. Adjuvant hormonal treatment was recommended to patients with positive lymph nodes. In 136/194 (70%) hormonal treatment was started within 3 months of surgery; 182/194 patients (93%) received early hormonal treatment within 1 year of surgery. 43/194 patients (22%) had had received neoadjuvant hormonal treatment prior to surgery. PSA values were considered only in patients without neoadjuvant hormonal treatment. The mean PSA in those without neoadjuvant hormonal treatment was 20.6 ng/ml. One patient for whom no Gleason score was available was excluded leaving 193 patients for survival analysis. The mean age was 64.3 years. The mean follow-up in the censored patients was 8.4 years.
Stratifications
After performing an exploratory analysis with three-sided stratifications of all variables (data not shown), two-sided stratification promising maximal contrast were used for further analyses. Besides tumor-related variables, the patients were stratified by age and four comorbidity classifications (the American Society of Anesthesiologists (ASA): physical status classification [3] , the New York Heart Association (NYHA) classification of cardiac insufficiency [4] , the classification of angina pectoris of the Canadian Cardiovascular Society (CCS) [5] and the Charlson score [6] ) ( tables 1-3 ).
Study Endpoints
Deaths from prostate cancer (presence of uncontrolled progressive disease at the time of death), deaths from competing causes (absence of uncontrolled progressive disease at the time of death) and death from any cause were the study endpoints.
Statistical Analysis
Mantel-Haenszel hazard ratios and Kaplan-Meier overall survival curves were calculated. Comparisons were made with the log-rank test. The impact of different causes of death was analyzed by competing risk analysis [7] . The related comparisons were made with the Pepe-Mori test. All p values are raw values. Cox proportional hazard models were used to determine the independent significance of prognostic variables. The statistical analyses were performed with own macros for the Statistical Analysis Systems (SAS Institute, Cary, N.C., USA) statistical package.
Results
The results of the univariate analysis with overall mortality as endpoint are shown in table 1 . In addition to age, numerous tumor-and comorbidity-related factors were significantly associated with overall mortality. Gleason score and tumor stage were significantly associated with disease-specific mortality whereas the number of involved nodes did not reach the significance level ( table 2 ) . Age, ASA classification and Charlson score were significantly associated with competing mortality ( table 3 ). Using 70 years as the threshold, in the multivariate analysis, only age, Gleason score and the number of involved nodes were identified as independent predictors of overall survival. Age lost, however, its independent prognostic significance when an age threshold of 65 years was chosen ( table 4 ). With the independent risk factors identified in the multivariate analysis with 70 years as age threshold, the patients were subdivided into risk groups with distinctly different overall and disease-specific survival rates ( fig. 1 , 2 ). Comparing patients with 0-1 versus 2-3 risk factors, overall, diseasespecific and competing mortality differed significantly ( table 5 ) .
Discussion
In this study, the survival rates in patients with positive lymph nodes at radical prostatectomy differed widely. A sizeable minority of almost one third of patients without additional adverse prognostic factors had an excellent long-term survival rate (90% overall and 97% disease-specific survival after 10 years; fig. 1 , 2 ). This was similar to that usually seen in patients with node-negative disease. In the most unfavorable subset comprising about 25% of node-positive patients, however, only less than 30% survived for 10 years or more after radical prostatectomy. However, even in this subgroup with poor survival only 37% of patients actually died from prostate cancer within 10 years ( fig. 1 , 2 ; table 5 ).
The 10-year overall (66 vs. 67%) and disease-specific (82 vs. 82%) survival rates in this study were narrowly exactly the same as in a large bi-centric series treated between 1988 and 2003 with the same mean number of removed lymph nodes (n = 14) [8] . Something higher survival rates (76 and 87%) were observed in the immediate hormonal treatment arm in the randomized trial by Messing et al. [9] , whereas in the deferred treatment arm (hormonal treatment at symptomatic progression) the corresponding figures were clearly lower (53 and 59%). With 60% (disease-specific survival) and 52% (overall survival), Schumacher et al. [10] reported survival rates narrowly identical with those in the deferred treatment arm in the randomized trial of Messing et al. [9] . The authors used a comparable deferred hormonal treatment regimen but a more extended lymph node dissection with an average of 22 removed nodes [10] . Extended lymph node dissection removing about 50% more lymph nodes [10] may be supposed to include more patients with low volume lymph node involvement. The impaired survival rate in the cited study [10] compared to the early treatment arm of the trial of Messing et al. [9] and the current study suggests that early (adjuvant) hormonal treatment has a greater impact on the outcome of lymph node-positive disease after radical prostatectomy than the number of removed nodes. This study confirms the prognostic significance of the threshold of 2 involved lymph nodes found by others [8, 10] . In agreement with these other studies [8, 10] , in our series, there was no significant difference between patients with 1 and 2 positive nodes (HR 1.41, 95% CI 0.63-3.16, p = 0.41 in univariate analysis). The Gleason score of the prostatectomy specimen was an independent prognostic factor identified in this ( table 3 ) as well as in several other studies [10] [11] [12] , whereas other authors did not find independent prognostic significance of the Gleason score in node-positive patients [2, 13] . The role of age as a prognostic factor in patients with positive lymph nodes in this study is difficult to interpret. Whereas with a threshold of 70 years, age was a strong independent predictor of overall survival, this was no longer the case when a threshold of 65 years was chosen ( table 4 ). An acceptance of higher comorbidity in men over 70 years referred for radical treatment with particularly unfavorable tumor-related risk factors could be a possible explanation of this phenomenon that vanished when the elderly subgroup is diluted by less strictly selected younger patients.
Whereas, generally, after radical prostatectomy competing mortality clearly outweighs prostate cancer-specific mortality [14] , in lymph node-positive patients the proportion of disease-specific mortality is higher [15] . In the current study, with 18% disease-specific and 15% competing mortality ( tables 1 , 2 ), this difference was, however, moderate. In contrast, in a recently published large multicentric study, disease-specific mortality superseded competing mortality at 10 years by 67-540% [15] . With 10-year survival differences between low-risk and high-risk groups of 32-47% ( table 1 ), the prognostic impact of comorbidity in the univariate analysis in this study with lymph node-positive patients was clearly higher than seen after radical prostatectomy in general. In a radical prostatectomy series from the pre-PSA era, there was only a 22% 10-year overall survival difference between the Charlson score classes 0 and 2 or higher [16] . In more recent studies, this difference was even lower with only 7-12% [17, 18] . In our series, both comorbidity and tumor-related variables seemed to be associated with the other endpoint to some extent ( tables 2 , 3 ). Since none U sing an age threshold of 65 years instead of 70 years eliminated age as an independent predictor of overall survival. With 65 years as threshold, already in the univariate analysis there was no detectable association between age and overall survival (HR 1.49, 95% CI 0.86-2.61, p = 0.16). Table 5 . Overall prostate cancer-specific and competing mortality in patients with 0-1 compared with patients with 2-3 of risk factors (Gleason score 8-10, >2 positive nodes and age ≥70 years)
C ategory
Cumulative mortality rate at 10 years Wh en age was disregarded as a risk factor and patients with 0-1 were compared with those with 2 risk factors, the survival differences were less clear (overall survival: 88 vs. 52%, p < 0.0001; prostate cancer-specific mortality: 15 vs. 36%, p = 0.06; competing mortality: 13 vs. 27%, p = 0.22). * log-rank test, ** Pepe-Mori test.
of the trends did reach the significance level, these small differences could be ignored. It may, however, be conceivable that there was some interaction between adverse tumor-related parameters and serious comorbidity resulting in particularly high mortality rates from both causes combined. Survival in progressive prostate cancer disease may well be negatively influenced by serious concomitant benign diseases and, conversely, progressive prostate cancer might have overproportionally increased mortality in patients with serious comorbidity. The finding of increased mortality both from prostate cancer and from competing causes in patients with 2-3 risk factors ( table 5 ) possibly supports this hypothesis. Since almost all patients in this sample received hormonal treatment, an aggravating effect of hormone ablation on preexisting comorbid conditions [19] may also be taken into consideration.
Altogether, the outcome of lymph node-positive patients was more heterogeneous than that of the general radical prostatectomy population. In the latter, in one large series, the overall survival rates ranged between 70% (positive nodes, age 70-79 years) and 98% (Gleason score 6, age ! 60 years) [15] . In contrast, in patients with positive lymph nodes in our study, the difference between the most (Gleason score ! 8, ! 3 positive nodes, ! 70 years, 90% 10-year overall survival) and the least favorable groups (2-3 of the risk factors Gleason score 8-10, 3 or more positive nodes, 70 years or older, 29% 10-year overall survival; fig. 1 ) was clearly higher. The wide prognostic spectrum of lymph node-positive prostate cancer should be taken into consideration when different treatment options (for instance radical prostatectomy or adjuvant radiotherapy) are compared. Even minor differences in the selection of good risks into the active treatment arms might result in outcome differences. The overall survival curve of the least favorable subset of patients in this study ( fig. 1 ) was narrowly congruent to that observed in patients in whom radical prostatectomy was aborted because of positive lymph nodes [20] . In contrast, the most favorable subset had a higher survival probability than lymph node-positive patients receiving adjuvant radiotherapy [21] . Although efforts have been undertaken to control for possible selection effects [20, 21] , uncertainties remain. It seems questionable whether it will possible to reliably evaluate more aggressive treatment strategies (which are most likely to be offered to patients with favorable risk factors) for node-positive disease without performing randomized trials. Several clinically meaningful questions deserve further investigation in randomized trials in this patient population, such as timing and duration of hormonal therapy, the role of radical prostatectomy in men with gross lymph node involvement and that of adjuvant radiotherapy.
This study has several limitations. The cause of death was determined by clinical judgment and not by autopsy. Due to the retrospective setting, there was no uniform follow-up regimen and it was not possible to reliably determine postoperative treatment details other than the timing of commencement of hormonal treatment and endpoints other than mortality. 22% of patients had received neoadjuvant hormonal treatment which can lead to false Gleason score upgrading [22] . We checked whether this effect was of relevance in this study and found no overall survival differences between patients with a Gleason score of 8-10 with and without neoadjuvant hormonal therapy (10-year survival 49.1% in patients with vs. 53.1% in patients without neoadjuvant hormonal therapy, HR 1.14, 95% CI 0.55-2.34, p = 0.73). Thus, it is unlikely that neoadjuvant hormonal therapy did impair the prognostic validity of the Gleason score in this sample. Therefore, we decided not to exclude patients with neoadjuvant hormonal treatment from analysis.
Conclusion
Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer (those with 2-3 of the risk factors age 70 years or older, Gleason score 8 or higher or more than 2 involved lymph nodes) may be attributed to increased competing mortality. Interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer may be discussed as a possible explanation for this observation.
